Swiss generic drugmaker Sandoz has officially filed a landmark draft anti-dumping complaint with the European Commission. The company warns that heavily subsidized Chinese imports of amoxicillin (the active ingredient in Europe’s most heavily relied-upon penicillin) are threatening to completely wipe out the continent’s remaining domestic manufacturing.
Thank you for reading this post, don't forget to subscribe!The Core Crisis: An Uneven Playing Field
The issue is not a sudden lack of demand, but market-distorting trade conditions. As Sandoz CEO Richard Saynor points out, life-saving antibiotics are being treated like cheap commodities, where a life-saving pack often costs less than a pack of chewing gum.
- The 90% Dependency: Up to 90% of global Active Pharmaceutical Ingredients (APIs) for antibiotics are now manufactured outside of Europe, heavily concentrated in China.
- Aggressive Underpricing: Sandoz alleges that Chinese manufacturers utilize heavy state subsidies to artificially lower prices. Chinese amoxicillin imports land in Europe at prices roughly 47% below European production costs.
- The Last Line of Defense: Sandoz operates the Kundl site in Austria, celebrating its 80th anniversary as the last fully vertically integrated penicillin facility left in Europe. If uneven competition forces it under, European independence vanishes.
“Safeguarding antibiotic supply is not only a health policy issue, but a question of economic security and strategic trade policy. Europe must act now to safeguard independent supply in years to come.”
— Richard Saynor, Sandoz CEO
National Security & Public Health Risks
| Threat | Direct Impact |
| Geopolitical Vulnerability | Total reliance on a single foreign nation for primary healthcare components means the continent’s medicine supply can easily be disrupted or used as economic leverage during international disputes. |
| Severe Drug Shortages | Europe is already plagued by recurring winter shortages of amoxicillin suspensions for children. Lacking domestic manufacturing infrastructure makes it impossible to quickly spin up emergency supply. |
| Hesitant Regulatory Action | While initiatives like the EU’s Critical Medicines Act target a 30% domestic sourcing benchmark, they currently lack enforcement teeth. |
Moving Forward
Sandoz is calling for immediate corrective action, urging the European Union to impose strict defensive tariffs and anti-dumping duties to prevent foreign firms from flooding the market below-cost. The company argues that Europe should follow the blueprint set by India, which previously executed minimum import prices to successfully shield its own domestic antibiotic supply chains from external market dumping.
